Loading...
•
Jun 30, 2021
Maravai Q2 2021 Earnings Report
Maravai reported strong revenue growth driven by Nucleic Acid Production and Biologic Safety Testing, and updated 2021 financial guidance.
Key Takeaways
Maravai LifeSciences reported a significant increase in revenue for Q2 2021, driven by strong growth in its Nucleic Acid Production and Biologic Safety Testing segments. The company's net income also saw a substantial rise compared to the same period last year. Maravai updated its 2021 revenue guidance upwards and announced an agreement for the divestiture of its Protein Detection business segment.
Revenue increased by 364.3% to $217.8 million in Q2 2021.
Net income reached $134.3 million for the second quarter.
2021 revenue guidance increased to a range of $745.0 million to $770.0 million.
Agreement reached for the divestiture of the Protein Detection business segment.
Maravai
Maravai
Maravai Revenue by Segment
Revenue by Segment
Nucleic Acid Production Revenue
CapyFin.comBiologics Safety Testing Revenue
CapyFin.com Forward Guidance
Maravai updated its financial guidance for the full year 2021, projecting total revenue between $745.0 million and $770.0 million, reflecting growth of 162.2% to 171.0%. Adjusted EBITDA is expected to be in the range of $515.0 million to $535.0 million, and Adjusted fully diluted EPS (non-GAAP) is expected to be in the range of $1.30 - $1.36 per share.
Positive Outlook
- Total revenue for 2021 is projected to be in the range of $745.0 million to $770.0 million, reflecting overall growth of 162.2% to 171.0%.
- Adjusted EBITDA (non-GAAP) is expected to be in the range of $515.0 million to $535.0 million.
- Adjusted fully diluted EPS (non-GAAP) is expected to be in the range of $1.30 - $1.36 per share.
- Guidance includes revenue contribution from our Protein Detection business from January 2021 through the anticipated closing of the sale to Thompson Street Capital Partners.
- Expectations for existing business.
Challenges Ahead
- Guidance does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified.
- Guidance is subject to a number of risks and uncertainties identified in the Forward-Looking Statements.
- Maravai cannot provide guidance for the most closely comparable GAAP measures or reconciliations for the non-GAAP financial measures included in the updated 2021 guidance above because we are unable to provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort.
- Inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including net income attributable to noncontrolling interest, variations in effective tax rate, expenses to be incurred for acquisition activities, and the diluted weighted average number of shares of Class A common stock outstanding for the applicable period from potential proforma exchanges of outstanding Class B common shares for shares of Class A common stock.
- Unable to present a quantitative reconciliation of the aforementioned forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures because such information is not available.
Revenue & Expenses
Visualization of income flow from segment revenue to net income